MB710

CAS No. 2230044-57-0

MB710( MB-710 )

Catalog No. M13571 CAS No. 2230044-57-0

MB710 is a small-molecule p53 mutant Y220C stabilizer, binds tightly to the Y220C pocket and stabilizes p53-Y220C in vitro.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 519 In Stock
5MG 471 In Stock
10MG 827 In Stock
25MG 1767 In Stock
50MG 2771 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    MB710
  • Note
    Research use only, not for human use.
  • Brief Description
    MB710 is a small-molecule p53 mutant Y220C stabilizer, binds tightly to the Y220C pocket and stabilizes p53-Y220C in vitro.
  • Description
    MB710 is a small-molecule p53 mutant Y220C stabilizer, binds tightly to the Y220C pocket and stabilizes p53-Y220C in vitro.
  • In Vitro
    Cell Viability Assay Cell Line:NUGC3 (mutant p53 Y220C), HUH-7 (mutant p53 Y220C), NUGC4 (p53 WT), HUH-6 cells (p53 WT)Concentration:0-200 μM Incubation Time:72 hours Result:Showed relatively low toxicity against all cell lines tested at concentrations up to 60?μM. NUGC3 was the most sensitive cell line.
  • In Vivo
    ——
  • Synonyms
    MB-710
  • Pathway
    Apoptosis
  • Target
    MDM2-p53
  • Recptor
    MDM2-p53
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2230044-57-0
  • Formula Weight
    457.286
  • Molecular Formula
    C16H16IN3O3S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 16.67 mg/mL (36.45 mM)
  • SMILES
    O=C(C1=C2N=C(N(CC)CC)SC2=C(N3C=CC=C3)C(I)=C1O)O
  • Chemical Name
    2-(diethylamino)-5-hydroxy-6-iodo-7-(1H-pyrrol-1-yl)benzo[d]thiazole-4-carboxylic acid

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Baud MGJ, et al. Eur J Med Chem. 2018 May 25;152:101-114.
molnova catalog
related products
  • Relugolix

    Relugolix is an orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity.

  • RO-2468

    A potent, selective, and orally active p53-MDM2 antagonist with IC50 of 6 nM.

  • Serdemetan

    Serdemetan (JNJ 26854165) is a novel anticancer agent that inhibits the function of the E3 ligase HDM2.